EUCTR2013-003174-27-FR进行中（未招募）不适用
A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA. - IFM2013-04
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 330
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A PHASE III STUDY OF VELCADE (BORTEZOMIB) DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA. - VD vesus VTDPATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, UNDER THE AGE OF 66, CANDIDATE FOR AUTOLOGOUS STEM CELL TRANSPLANTATIONMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2007-005204-40-FRIntergroupe Francophone du Myélome200
进行中（未招募）
不适用
A PHASE III STUDY OF VELCADE (BORTEZOMIB)-DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB)-THALIDOMIDE-DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA - VD versus VTDPATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, UNDER THE AGE OF 66, CANDIDATE FOR AUTOLOGOUS STEM CELL TRANSPLANTATIONMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2007-005204-40-BEIntergroupe Francophone du Myélome200
已完成
3 期
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)Multiple MyelomaNCT01971658Nantes University Hospital358
进行中（未招募）
不适用
A PHASE II STUDY OF VELCADE BORTEZOMIB - PS341 IN THE TREATMENT OF PATIENTS OVER 18 YEARS WITH Ph LEUKEMIApatients over 18 years with Ph leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2004-002977-22-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
进行中（未招募）
1 期
PHASE II TRIAL OF BORTEZOMIB (VELCADE®) IN PATIENTS WITH ADVANCED OR RELAPSED LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)EUCTR2005-003077-25-ATAKH Vienna16